F/M Investments’s Novo Nordisk NVO Stock Holding History

F/M Investments’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-126,633	Closed	-$7.03M	–	450
2025 Q3	$7.03M	Sell	126,633 -1,829	-1%	-$107K	0.27%	90
2025 Q2	$8.87M	Sell	128,462 -522	-0.4%	-$35.5K	0.32%	66
2025 Q1	$8.96M	Sell	128,984 -1,382	-1%	-$114K	0.36%	61
2024 Q4	$11.2M	Sell	130,366 -50,355	-28%	-$5.45M	0.41%	50
2024 Q3	$21.5M	Sell	180,721 -794	-0.4%	-$106K	0.68%	25
2024 Q2	$25.9M	Buy	+181,515	New	+$24.1M	0.94%	18

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

F/M Investments's NVO Position: Q4 2025 in Review

F/M Investments sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 126,633 shares — an estimated $7.03M sold.

F/M Investments first reported a position in NVO in Q2 2024 and held it in 6 quarters. The position peaked at $25.9M in Q2 2024. 1,418 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

F/M Investments reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
F/M Investments sold 126,633 Novo Nordisk shares in Q4 2025, an estimated $7.03M.
F/M Investments first reported a position in Novo Nordisk in Q2 2024 and held it in 6 quarters.
F/M Investments's Novo Nordisk position peaked at $25.9M in Q2 2024.
1,418 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on F/M Investments's 13F filing for Q4 2025, filed 3 Feb 2026.